Sionna Therapeutics Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis ...
Industry growth reports; new GF CEO; UVM for mixed signal; power demands explode; EU-US chip collaboration; earnings; S Korea ...
The gross proceeds from the initial public offering are expected to be approximately $191 million, before deducting underwriting discounts and commissions and other offering expenses, and excluding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback